Table 2.
Characteristics of case participants with COVID-19 after their first or second vaccination and unvaccinated control participants with COVID-19 in the disease profile analysis
|
Cases 3 |
Cases 4 |
Controls 3 |
Controls 4 |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total (n=3825) | 18–59 years (n=2320) | ≥60 years (n=1505) | Total (n=906) | 18–59 years (n=455) | ≥60 years (n=451) | Total (n=3825) | 18–59 years (n=2363) | ≥60 years (n=1462) | Total (n=906) | 18–59 years (n=474) | ≥60 years (n=432) | ||
| Demographics | |||||||||||||
| Sex | |||||||||||||
| Female | 2460 (64·3%) | 1578 (68·0%) | 882 (58·6%) | 561 (61·9%) | 305 (67·0%) | 256 (56·8%) | 2462 (64·4%); p=0·98 | 1590 (67·3%); p=0·60 | 872 (59·6%); p=0·58 | 553 (61·0%); p=0·74 | 296 (62·4%); p=0·15 | 257 (59·5%); p=0·41 | |
| Male | 1365 (35·7%) | 742 (32·0%) | 623 (41·4%) | 345 (38·1%) | 150 (33·0%) | 195 (43·2%) | 1363 (35·6%) | 773 (32·7%) | 590 (40·4%) | 353 (39·0%) | 178 (37·6%) | 175 (40·5%) | |
| Age, years | 52·0 (14·2) | 43·2 (9·0) | 65·6 (9·0) | 54·5 (14·3) | 43·4 (9·6) | 65·7 (8·4) | 51·5 (14·2); p=0·20 | 42·9 (9·3); p=0·25 | 65·4 (8·8); p=0·22 | 53·7 (13·8); p=0·55 | 43·6 (9·6); p=0·36 | 64·9 (7·9); p=0·084 | |
| Body-mass index, kg/m2 | 27·2 (6·8) | 27·3 (6·9) | 27·1 (6·7) | 26·9 (7·3) | 27·3 (7·7) | 26·5 (7·0) | 27·2 (6·6); p=0·71 | 27·3 (6·8); p=0·44 | 27·1 (6·2); p=0·28 | 26·9 (6·7); p=0·83 | 27·2 (7·0); p=0·45 | 26·6 (6·2); p=0·19 | |
| Health-care worker | 683 (17·9%) | 475 (20·5%) | 208 (13·8%) | 124 (13·7%) | 90 (19·8%) | 34 (7·5%) | 572 (15·0%); p=0·0006 | 393 (16·6%); p=0·0008 | 179 (12·2%); p=0·21 | 91 (10·0%); p=0·020 | 58 (12·2%); p=0·0022 | 33 (7·6%); p=1·0 | |
| Comorbidities | |||||||||||||
| Frailty | 215 (5·6%) | 49 (2·1%) | 166 (11·0%) | 51 (5·6%) | 14 (3·1%) | 37 (8·2%) | 138 (3·6%); p<0·0001 | 24 (1·0%); p=0·0029 | 114 (7·8%); p=0·0031 | 21 (2·3%); p=0·0004 | 4 (0·8%); p=0·016 | 17 (3·9%); p=0·018 | |
| Presence of at least one comorbidity | 891 (23·3%) | 453 (19·5%) | 438 (29·1%) | 236 (26·0%) | 111 (24·4%) | 125 (27·7%) | 809 (21·2%); p=0·026 | 391 (16·5%); p=0·0087 | 418 (28·6%); p=0·78 | 207 (22·8%); p=0·13 | 76 (16·0%); p=0·0018 | 131 (30·3%); p=0·41 | |
| Disease characteristics* | |||||||||||||
| Asymptomatic infection | 672/3683 (18·2%) | 331/2234 (14·8%) | 341/1449 (23·5%) | 183/887 (20·6%) | 66/444 (14·9%) | 117/443 (26·4%) | 414/3445 (12·0%); p<0·0001 | 242/2121 (11·4%); p=0·0009 | 172/1324 (13·0%); p<0·0001 | 98/835 (11·7%); p<0·0001 | 45/425 (10·6%); p=0·067 | 53/410 (12·9%); p<0·0001 | |
| Hospitalised | 147/3791 (3·9%) | 64/2298 (2·8%) | 83/1493 (5·6%) | 20/897 (2·2%) | 11/451 (2·4%) | 9/446 (2·0%) | 397/3726 (10·7%); p<0·0001 | 142/2297 (6·2%); p<0·0001 | 255/1429 (17·8%); p<0·0001 | 64/867 (7·4%); p<0·0001 | 18/445 (4·0%); p=0·19 | 46/422 (10·9%); p<0·0001 | |
| More than five reported symptoms | 551/2479 (22·2%) | 368/1430 (25·7%) | 183/1049 (17·4%) | 121/592 (20·4%) | 71/286 (24·8%) | 50/306 (16·3%) | 868/2762 (31·4%); p<0·0001 | 515/1540 (33·4%); p<0·0001 | 353/1222 (28·9%); p<0·0001 | 141/482 (29·3%); p=0·0010 | 71/223 (31·8%); p=0·090 | 70/259 (27·0%); p=0·0027 | |
| Symptoms lasting ≥28 days | 229/2479 (9·2%) | 124/1430 (8·7%) | 105/1049 (10·0%) | 31/592 (5·2%) | 9/286 (3·1%) | 22/306 (7·2%) | 296/2762 (10·7%); p=0·080 | 121/1540 (7·9%); p=0·42 | 175/1222 (14·3%); p=0·0020 | 55/482 (11·4%); p=0·0002 | 16/223 (7·2%); p=0·040 | 39/259 (15·1%); p=0·0040 | |
| Reporting | |||||||||||||
| Duration of reporting, days | 180·7 (51·5) | 174·4 (55·6) | 191·4 (41·5) | 192·1 (42·7) | 184·5 (49·9) | 201·0 (30·0) | 155·7 (64·6); p<0·0001 | 150·4 (65·8); p<0·0001 | 164·4 (61·7); p<0·0001 | 178·7 (51·0); p<0·0001 | 171·3 (55·9); p=0·0006 | 186·7 (43·7); p<0·0001 | |
| Proportion of missing daily reports, % | 50% (30) | 60% (30) | 50% (20) | 50% (30) | 60% (30) | 40% (20) | 60% (30); p<0·0001 | 70% (30); p<0·0001 | 50% (30); p=0·13 | 60% (30); p<0·0001 | 70% (30); p=0·0011 | 50% (30); p=0·48 | |
Data are n (%), n (%); p value, n/N (%), n/N (%); p value, or mean (SD). The p values indicate the difference between cases 3 and controls 3, or between cases 4 and controls 4, and were not adjusted for multiple testing.
*
Only users with information on hospitalisation, symptoms, and disease duration were included in the analysis.